Therapeutic goals and treatment response evaluation in moderate to severe psoriasis: an experts opinion document

被引:17
作者
Belinchon Romero, Isabel [1 ]
Dauden, Esteban [2 ]
Ferrandiz Foraster, Carlos [3 ,4 ]
Gonzalez-Cantero, Alvaro [5 ]
Carrascosa Carrillo, Jose Manuel [3 ,4 ]
机构
[1] Hosp Gen Univ Alicante ISABIAL UMH, Dept Dermatol, Alicante, Spain
[2] Hosp Univ La Princesa, Inst Invest Sanitaria La Princesa IIS IP, Dept Dermatol, Madrid, Spain
[3] Hosp Badalona Germans Trias & Pujol, Dept Dermatol, Badalona, Spain
[4] Univ Autonoma Barcelona, IGTP, Barcelona, Spain
[5] Hosp Univ Ramon Y Cajal, Dept Dermatol, Madrid, Spain
关键词
Psoriasis; therapeutic objective; treatment response; systematic literature review; Delphi; SYSTEMIC TREATMENTS; BIOLOGIC THERAPY; GUIDELINES; PREVALENCE; VULGARIS; SPAIN;
D O I
10.1080/07853890.2021.1986637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To critically analyse and define therapeutic objectives, response to treatment evaluation and related decisions in psoriasis. Methods Expert consensus meetings, a systematic and narrative reviews and a collaborative Delphi procedure were carried out. A steering committee from the Spanish Group of Psoriasis was established who based on the reviews generated a set of related statements. Subsequently, a group of 40 experts tested their agreement with the statements, through 3 Delphi rounds. Results We found a great variability in clinical guidelines regarding to the definition of treatment goal and the response. In general, treatment failure was considered if a PASI50 is not achieved. The panel of experts agreed on (1) clearly differentiate between ideal and a realistic goals when establishing the therapeutic goal in moderate to severe psoriasis; (2) treatment goals should be in general established regardless of the type of drug for psoriasis; (3) treatment failure if PASI75 response is not reached; (4) an absolute PASI is in general preferred to the rate of PASI improvement from baseline; (5) disease characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals. Conclusions A clear treatment decision making framework is vital to improve management of psoriasis. KEY MESSAGES Psoriasis characteristics, patients and physicians opinions/needs and treatment adherence influence treatment goals. Different disease indexes could be used to assess treatment response but absolute PASI is preferred In general psoriasis treatment failure should be considered if PASI75 response is not reached
引用
收藏
页码:1727 / 1736
页数:10
相关论文
共 30 条
[1]   French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults [J].
Amatore, F. ;
Villani, A. -P. ;
Tauber, M. ;
Viguier, M. ;
Guillot, B. ;
Aubin, Francois ;
Bachelez, Herve ;
Beneton, Nathalie ;
Beylot-Barry, Marie ;
Jullien, Denis ;
Mahe, Emmanuel ;
Paul, Carle ;
Richard, Marie-Aleth .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) :464-483
[2]   Patient-physician discrepancy in the perception of immune-mediated inflammatory diseases: rheumatoid arthritis, psoriatic arthritis and psoriasis. A qualitative systematic review of the literature [J].
Antonio Sacristan, Jose ;
Dilla, Tatiana ;
Diaz-Cerezo, Silvia ;
Gabas-Rivera, Clara ;
Aceituno, Susana ;
Lizan, Luis .
PLOS ONE, 2020, 15 (06)
[3]   Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis [J].
Armstrong, April W. ;
Puig, Luis ;
Joshi, Avani ;
Skup, Martha ;
Williams, David ;
Li, Junlong ;
Betts, Keith A. ;
Augustin, Matthias .
JAMA DERMATOLOGY, 2020, 156 (03) :258-269
[4]   Treatment goals for moderate to severe psoriasis: An Australian consensus [J].
Baker, Christopher ;
Mack, Alexandra ;
Cooper, Alan ;
Fischer, Gayle ;
Shumack, Stephen ;
Sidhu, Shireen ;
Soyer, Peter ;
Wu, Jason ;
Chan, Jonathan ;
Nash, Peter ;
Rawlin, Morton ;
Radulski, Barbara ;
Foley, Peter .
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2013, 54 (02) :148-154
[5]  
Baker EL, 2012, DERMATOLOGY THER, V2, DOI 10.1007/s13555-012-0009-3
[6]   Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature [J].
Belinchon, I. ;
Rivera, R. ;
Blanch, C. ;
Comellas, M. ;
Lizan, L. .
PATIENT PREFERENCE AND ADHERENCE, 2016, 10 :2357-2367
[7]   Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice [J].
Chalmers, Robert J. G. .
DERMATOLOGIC CLINICS, 2015, 33 (01) :57-+
[8]   Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology [J].
Dauden, E. ;
Puig, L. ;
Ferrandiz, C. ;
Sanchez-Carazo, J. L. ;
Hernanz-Hermosa, J. M. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 :1-18
[9]   Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy [J].
Elmets, Craig A. ;
Lim, Henry W. ;
Stoff, Benjamin ;
Connor, Cody ;
Cordoro, Kelly M. ;
Lebwohl, Mark ;
Armstrong, April W. ;
Davis, Dawn M. R. ;
Elewski, Boni E. ;
Gelfand, Joel M. ;
Gordon, Kenneth B. ;
Gottlieb, Alice B. ;
Kaplan, Daniel H. ;
Kavanaugh, Arthur ;
Kiselica, Matthew ;
Kivelevitch, Dario ;
Korman, Neil J. ;
Kroshinsky, Daniela ;
Leonardi, Craig L. ;
Lichten, Jason ;
Mehta, Nehal N. ;
Paller, Amy S. ;
Parra, Sylvia L. ;
Pathy, Arun L. ;
Prater, Elizabeth A. Farley ;
Rupani, Reena N. ;
Siegel, Michael ;
Strober, Bruce E. ;
Wong, Emily B. ;
Wu, Jashin J. ;
Hariharan, Vidhya ;
Menter, Alan .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (03) :775-804
[10]   Prevalence of Psoriasis in Spain in the Age of Biologics [J].
Ferrandiz, C. ;
Carrascosa, J. M. ;
Toro, M. .
ACTAS DERMO-SIFILIOGRAFICAS, 2014, 105 (05) :504-509